Belimumab demonstrates notable efficacy for enhancing treatment outcomes among adults with active systemic lupus erythematosus when added to standard therapy. Belimumab demonstrates notable efficacy ...

A new study found that people with cytomegalovirus (CMV) infection may be more likely to develop systemic lupus erythematosus (SLE), and CMV could influence how the disease starts.

A Phase II study was subsequently performed by the LBSL02/99 group, which enrolled 449 patients who met American College of Rheumatology (ACR) diagnostic criteria for SLE, had active SLE disease and ...

Johnson & Johnson said it will initiate a Phase 3 trial of its treatment for systemic lupus erythematosus, or SLE, after a recent study of the therapy met its primary endpoint. The company said ...

The 200mg single-dose prefilled autoinjector allows pediatric patients to receive SLE treatment at home via SC administration. The Food and Drug Administration (FDA) has approved Benlysta (belimumab) ...

The following transcript is automatically generated and may contain typos or misspellings. Please listen to the episode for the most accurate language. Dr. Susan Manzi 0:00 Hello everyone. I'm Dr.

The study is aimed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), preliminary efficacy and biomarkers of orelabrutinib in patients with mild to moderate SLE who ...

As The European Lupus Society’s 15th annual soiree approaches, the Clinical Trials Arena team takes a look at four promising therapies in the SLE pipeline.

The systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the seven major markets (7MM: the USA, France, ...